A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer ; volume:5 ; number:1 ; day:25 ; month:6 ; year:2012 ; pages:1-7 ; date:12.2012
Journal of ovarian research ; 5, Heft 1 (25.6.2012), 1-7, 12.2012
- Urheber
-
Defferrari, Carlotta
Campora, Sara
D'Amico, Mauro
Piccardo, Arnoldo
Biscaldi, Ennio
Rosselli, Daniela
Pasa, Ambra
Puntoni, Matteo
Gozza, Alberto
Gennari, Alessandra
Zanardi, Silvia
Lionetto, Rita
Bandelloni, Michela
DeCensi, Andrea
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1757-2215-5-17
- URN
-
urn:nbn:de:101:1-2021082206343662455327
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Defferrari, Carlotta
- Campora, Sara
- D'Amico, Mauro
- Piccardo, Arnoldo
- Biscaldi, Ennio
- Rosselli, Daniela
- Pasa, Ambra
- Puntoni, Matteo
- Gozza, Alberto
- Gennari, Alessandra
- Zanardi, Silvia
- Lionetto, Rita
- Bandelloni, Michela
- DeCensi, Andrea
- SpringerLink (Online service)
Ähnliche Objekte (12)
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients
Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
177 Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
Therapeutic options in heavily pretreated HIV-1 patients based on the genotypic resistance patterns
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients
Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
177 Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
Therapeutic options in heavily pretreated HIV-1 patients based on the genotypic resistance patterns
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients
Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
177 Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
Therapeutic options in heavily pretreated HIV-1 patients based on the genotypic resistance patterns
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report